Through the collaboration, the organizations will work to find potential inhibitors of the main protease of SARS-CoV-2, which is required for viral replication. The DDD platform will mine Medivir's proprietary protease-targeted compound library to identify putative inhibitors and evaluate active compounds as potential drug development candidates. Data for the top 100 candidates will be released online and made freely available for drug development purposes.

The project is spearheaded by Kristian Sandberg, PhD, co-director of SciLifeLab's DDD platform and principle investigator of the Nevermore COVID project. This project is part of Sweden's national research program, funded by the Knut and Alice Wallenberg Foundation with a total of $54 million. The program focuses on establishing precompetitive, open science collaboration at SciLifeLab by engaging both industry and academic research groups for the discovery of antivirals for SARS-CoV-2.

Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.

Getting to the heart of SARS-CoV-2 protease; a main drug target
X-ray crystallography performed at room temperature of the main protease of SARS-CoV-2 may be more physiologically relevant than standard low-temperature...

Computer tools shorten development time for SARS-CoV-2 drugs
Computer-based tools are helping researchers find potentially promising candidates for vaccines and treatments for SARS-CoV-2 -- and much more quickly...

Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating...

Does SARS-CoV-2 use host defenses to infect susceptible cells?
A new study pinpoints the most likely cell types that SARS-CoV-2 infects. Unexpectedly, the study indicates that one of the body's main defenses against...